About this trial
This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Karnofsky Performance Status ≥ 60
Histologically verified primary cancer disease
MRI findings indicating BM
Disqualifiers
Confirmed hematological malignity
Small-cell (lung) carcinoma
Peracute condition requiring immediate neurosurgical intervention
History of whole-brain radiotherapy (WBRT)
Trial design
Treatments tested in this trial
- Neoadjuvant Stereotactic Radiotherapy (NaSRT)
- Postoperative Stereotactic Radiotherapy (SRT)
Treatment groups
Sponsors and collaborators
University Hospital Ostrava
Lead sponsor
University Hospital Olomouc
Collaborator
Masaryk Memorial Cancer Institute
Collaborator
University Hospital Hradec Kralove
Collaborator